4.8 Million Veterans Have Used Psychedelics. Half Don't Know If They Can Tell Their Doctor.

4.8 Million Veterans Have Used Psychedelics. Half Don't Know If They Can Tell Their Doctor.

A new study from RAND puts a number on something the Department of Veterans Affairs has never had to answer for: an estimated 4.8 million American veterans have used psychedelic drugs. That is roughly 27.5% of all veterans, and it covers psilocybin mushrooms, LSD, and MDMA. The number itself is striking. What sits underneath it is the actual story. About half of veterans surveyed did not know whether telling their VA doctor about that use would put their benefits at risk. So they don't tell them.

What the study actually found

The research, published by the Washington think tank in June 2026, looked at three things: how many veterans have used psilocybin, LSD, and MDMA, how much they support legalizing those substances, and how well they understand the VA's rules about them.

LSD turned out to be the most commonly used of the three, and veterans were more likely than the general population to have used it at some point in their lives. Support for legal use was lower than the usage figures might suggest: 23% backed legal psilocybin mushrooms, 11% backed legal LSD, and 9% backed legal MDMA, roughly the same level of MDMA support as the country at large. Ibogaine, a powerful hallucinogen derived from an African shrub that has drawn heavy federal attention lately, had been used by less than 1% of veterans, though about 5% of those who hadn't tried it said they would be willing to.

That gap between use and support is worth sitting with. A lot of veterans in this data are using substances they are not campaigning to legalize. Which fits the picture the rest of the study paints: this is not an advocacy movement. It's people quietly trying to feel better.

The part nobody has fixed

Here is the finding that matters most. Lead author Michelle Priest noted that VA policy on psychedelics remains unclear, and that roughly half of veterans were unsure whether they could discuss the subject with a VA physician. She pointed out that the uncertainty carries real weight given how prominently veterans feature in psychedelic policy debates at both the federal and state level.

Think about what that means in an exam room. A veteran is being treated for PTSD, depression, or chronic pain. They have taken psilocybin, or they are considering it. Their doctor needs that information to prescribe safely, because some of these substances interact badly with common psychiatric medications. But the veteran doesn't know if saying it out loud costs them the disability compensation they live on. So the doctor doesn't get told, and treats a patient whose actual situation is hidden from them.

The marijuana precedent makes the silence look worse

This is not a hypothetical problem the VA has never encountered. The agency solved the exact same problem for a different substance in 2023, when it issued guidance actively encouraging veterans to talk to their doctors about marijuana use, and stated plainly that using it would not affect their benefits.

No equivalent guidance exists for psychedelics. RAND flagged this directly. The VA has demonstrated it knows how to write this document, understands why it's necessary, and has done it before. It simply has not done it here.

Asked about the study, a VA spokesperson pointed reporters to the department's existing webpage. That page discourages veterans from self-medicating or from swapping proven mental health treatments for psychedelics or other unprescribed substances, notes that evidence-based treatments are available at VA facilities, and advises veterans to consult their providers before making treatment decisions.

Read that carefully. It tells veterans not to do the thing, and tells them to talk to their provider. It does not tell them what happens to their benefits if they admit they already did the thing. That is the precise question 4.8 million people need answered, and it is the one question the page leaves open.

Meanwhile, the federal government is spending heavily on this

The policy silence is stranger in context, because Washington is not ignoring psychedelics. It is funding them aggressively.

The Defense Department committed $9.8 million to studying psychedelics for active-duty troops. Walter Reed National Military Medical Center received a $4.9 million defense grant to study MDMA's effects on active-duty soldiers with post-traumatic stress disorder. In April 2026, President Trump signed an executive order committing at least $50 million in federal funds to expand ibogaine research, and directing the FDA to speed up reviews of certain psychedelic therapies. At the signing, he described veteran suicide as a national tragedy and framed the effort as being for the military in particular. Following the order, the VA announced its own clinical trial evaluating MDMA-assisted therapy for severe mental health disorders.

So the same federal government that is spending tens of millions of dollars studying whether these substances can help veterans has not gotten around to telling veterans whether they can mention them to a doctor without losing their benefits. Both things are true at once. The research pipeline is moving fast and the patient-facing guidance is standing still.

Why this is a harm-reduction problem, not a culture-war one

Strip away the politics and what remains is a clinical safety issue.

When patients hide substance use from physicians, the physicians make worse decisions. That is not a controversial claim, it is the entire reason doctors ask. Psychedelics can interact with medications that veterans are commonly prescribed, including certain antidepressants. Some of these substances carry real cardiac risk. Ibogaine in particular has a documented association with dangerous heart rhythm effects, which is part of why it is being studied under supervision rather than handed out. A veteran who takes it without telling anyone is taking it without a safety net.

There is also the population involved. This is a group with elevated rates of PTSD, depression, and suicide, which is exactly why the federal government cited veteran suicide when it opened the funding taps. Building a system where those specific people feel they must lie to their doctors to protect their income is a bad outcome no matter what anyone thinks about drug policy.

What veterans can actually do right now

We are not going to pretend a blog post resolves a federal policy gap. But a few things are worth knowing.

The VA's stated position is that veterans should consult their providers before making treatment decisions, and that evidence-based treatments are available now through VA facilities. If you are considering psychedelics because existing treatment isn't working, that is a conversation worth having with a provider, and there are VA-run clinical trials actively recruiting, including MDMA-assisted therapy research. A trial is a setting where you can access these substances legally, under medical supervision, without hiding anything.

Veterans service organizations and VA patient advocates can also help you understand what does and does not affect your benefits, and they are a lower-risk place to ask the question than guessing on your own.

If you are struggling, the Veterans Crisis Line is available around the clock. Dial 988 and press 1, or text 838255.

The bottom line

RAND found that nearly 5 million veterans have used psychedelics and that half of them don't know whether their own doctor is a safe person to tell. The VA already fixed this exact problem for marijuana three years ago and has not repeated the exercise here, even as tens of millions of federal dollars flow into psychedelic research aimed squarely at this population. The fix is not complicated. It is a page of guidance saying what happens to a veteran's benefits when they are honest. Until that page exists, the government is funding research into a treatment while the intended patients stay quiet in the exam room.

This article is educational and is not medical advice. It is not an endorsement or recommendation of psychedelic use. Psilocybin and other substances discussed here remain illegal under federal law and in most states.